摘要
氨磷汀是第一个被认可的广谱细胞保护药。本文概述了氨磷汀的药动学、作用机制以及在肿瘤的放、化疗中所显示的与器官特异性细胞保护药不同的高效、低毒、全面的正常细胞保护作用 ,不影响抗癌治疗效果。氨磷汀在各人群的安全性已得到临床证实。
Amifostine (WR 2721) is the first confirmed cytoprotector of broad spectrum. The article recommends amifostine including its pharmacokinetics, the mechanism of action, and clinical use in radiotherapy and chemotherapy of tumours which is different from special tissues protectors. Amifostine is high efficiency, low toxin, and broad spectrum, it can protects normal tissues from radiotherapy or chemotherapy induce toxity and not confusion the antitumor effects. The safety of amifostine is also verified in kinds of people.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2003年第2期108-112,共5页
Chinese Journal of New Drugs and Clinical Remedies
关键词
广谱细胞保护药
氨磷汀
药动学
放射疗法
化学疗法
amifostine
pharmacokinetics
radiotherapy
chemotherapy, adjuvent
dexrazoxane
